Creation of optimal nucleic acid medicine for disease treatment with proprietary technology
PURMX's solution is a drug discovery seed of small RNA nucleic acid drugs that fine-tune many target genes and deliver unprecedented therapeutic effects. PURMX already possesses a large amount of functional RNA screening data, which is being further expanded.
The first stage of innovative nucleic acid medicine seeds is MIRX002. MIRX002 is a nucleic acid medicine for malignant pleural mesothelioma. We have completed non-clinical trials and are conducting investigator-initiated clinical trials at Hiroshima University Hospital starting in 2021.
Company Details
- Employees
- 11
- Founded
- 2021
- Address
- 1-2-3 Kasumi, Minami-Ku, Hiroshima,hiroshima 734-0037,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.purmx.com
- Keywords
- targetting pharma and bio..
- HQ
- Hiroshima, Hiroshima
Purmx Therapeutics,inc. Questions
Purmx Therapeutics,Inc.'s website is https://www.purmx.com
Purmx Therapeutics,Inc.'s LinkedIn profile is https://jp.linkedin.com/company/purmx
Purmx Therapeutics,Inc. has
11 employees.
View email and phone details for 11
employees at Purmx Therapeutics,Inc..
Purmx Therapeutics,Inc.'s industry is
Biotechnology Research
Purmx Therapeutics,Inc.'s top competitors are
Celaid Therapeutics,
Valliance Sénégal,
Jy Biomed,
Editforce Inc.,
株式会社メディカルフォース,
Sixpeaks Bio,
Eg Biomed,
Yd Biopharma,
Molmir, Inc,
Scad (Stem Cell & Device Laboratory, Inc. ).
Purmx Therapeutics,Inc.'s categories are Biotechnology Research
Purmx Therapeutics,Inc.'s founding year is 2021
